By Brad Sorensen, CFA
NASDAQ:LGVN
READ THE FULL LGVN RESEARCH REPORT
Longeveron (NASDAQ:LGVN) is a clinical-stage biotechnology company that has positioned itself in the regenerative medicine space with a potentially life-changing therapeutic candidate. Its flagship product, laromestrocel, is an allogeneic medicinal-signaling cell (MSC) therapy derived from young healthy adult donors and manufactured under current good manufacturing practice. The science behind laromestrocel rests on the idea that these MSCs may provide anti-inflammatory, pro-vascular, and regenerative support in tissues that are damaged or under stress. The company behind these exciting developments is at an inflection point in our view, with a good opportunity to achieve many of the goals discussed in the near future.
To further that goal, Longeveron Inc. recently announced a new private placement financing that could provide the company with up to $30 million in total gross proceeds, structured in two tranches and led by institutional investors.
The first tranche is expected to generate approximately $15 million at closing, with participation from investors including Coastlands Capital and Janus Henderson Investors, while H.C. Wainwright is serving as the exclusive placement agent. The financing is priced at $0.52 per share, roughly at-the-market under Nasdaq rules. In the initial closing, the company will issue about 6.0 million shares of Class A common stock, along with Series A non-voting convertible preferred shares that are convertible into roughly 22.8 million additional common shares at the same $0.52 conversion price.
The agreement also includes a second potential tranche of up to $15 million, which would be funded if certain conditions are met. Those conditions are tied primarily to clinical milestones related to the Phase 2b ELPIS II trial in hypoplastic left heart syndrome (HLHS) and the company’s share price performance.
An additional element of the deal gives investors an interest in 50% of proceeds from any future sale of a Rare Pediatric Disease Priority Review Voucher, should the company receive one from the FDA in connection with its laromestrocel therapy for HLHS.
Management stated that the proceeds, combined with existing cash, are expected to fund operations into the fourth quarter of 2026, carrying the company beyond the anticipated top-line data readout from the pivotal ELPIS II trial in the third quarter of 2026. Funds will primarily support clinical development of the company’s stem-cell therapy laromestrocel, along with working capital and general corporate purposes.
Overall, the financing provides LGVN with near-term capital to advance its lead clinical program while tying a portion of the funding to upcoming clinical milestones, though it also introduces potential dilution through convertible securities tied to the $0.52 conversion price.
We want to remind investors why this funding is so important due to the progress made on treating HLHS, which is a rare and life-threatening congenital heart defect in which the left ventricle is severely underdeveloped or absent, meaning that the right ventricle must be adapted to handle systemic circulation. Even with the standard of care—typically a series of three reconstructive surgeries over the first few years of life—survival into adolescence is only around 50–60%.
Longeveron’s approach has been to administer laromestrocel directly into the right ventricle (or the myocardium of the right ventricle) during the second stage of surgery (the “Glenn” procedure, typically at around 4 months of age). Company scientists believe that by improving the function of the systemic right ventricle—through regenerative mechanisms—the therapy should improve transplant-free survival and long-term outcomes for these infants.
The company reported Phase 1 results (called ELPIS I) in ten infants. In that study, laromestrocel was well tolerated: there were no major adverse cardiovascular events or infections related to therapy through one year, meeting the primary safety endpoint. Even more striking, long-term follow-up showed 100 % transplant-free survival up to five years in those patients, compared to historical controls (approximately 83 % at five years, with ~5 % requiring transplant) in the comparable population.
Building on that, Longeveron is now conducting a pivotal Phase 2b trial (ELPIS II-mentioned above). The trial is designed to compare Laromestrocel plus standard surgery versus standard surgery alone, with endpoints including survival at 12 months, length of hospitalization and change in right ventricular ejection fraction between baseline and 12 months. Full enrollment was achieved in June 2025, with topline results, as mentioned above, anticipated in the third quarter of 2026 after a 12-month follow-up.
On the regulatory front, the program has very strong designations. The U.S. Food and Drug Administration has approved three special designations for laromestrocel in the HLHS indication: Rare Pediatric Disease (RPD) designation, Orphan Drug Designation (ODD), and Fast Track designation. Importantly, following a Type C meeting with FDA in September 2024, the agency confirmed that the ELPIS II trial could serve as a pivotal study—and if positive, could form the basis for a Biologics License Application (BLA) submission for full traditional approval.
Summary
We continue to believe that Longeveron is an exciting clinical-stage company, and investors aren’t appropriately appreciating the game-changing potential laromestrocel may be able to have on multiple serious medical conditions. As a result of the prudent decisions made by management, we believe laromestrocel will ultimately have a substantial impact on the health situations of thousands of patients. We believe the stock continues to be underpriced as investors aren’t appreciating the potential of laromestrocel and encourage investors to take a look at LGVN.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.